The company has issued more shares over this period, which dilutes each existing shareholder’s stake.
Diluted shares outstanding: 304.8M (2021) → 313.1M (2025)
Faes Farma, S.A. is a pharmaceutical enterprise dedicated to the research, development, manufacture, and distribution of both finished medicinal products and crucial raw materials. Its extensive operations span Spain and a multitude of international markets. The company's comprehensive product line encompasses prescription drugs, generic alternatives, over-the-counter (OTC) remedies, nutritional supplements, infant formula, and various other health-related items. Among its diverse offerings are Actimag (a magnesium pidolate), the anti-allergic Bilaxten, the anti-infective Bronquidiazina CR, Claversal for ulcerative colitis and Crohn's disease, the corticoid Dezacor, the anti-inflammatory Dolotren (also available as Dolotren Gel), Dynamogen (an anti-anorexic), Ferroprotina (an anti-anaemic), Hidroferol, Lipofen, Positon for dermatological conditions, strength-enhancing products such as Potenciator and Surmenalit, the laxative Pruina, the muscle relaxant and analgesic Robaxisal Compuesto, Trausan (a citicoline-based product), the venous vasoprotector Venosmil (and Venosmil Gel), and the anti-influenza medication Yendol. Furthermore, Faes Farma provides key active pharmaceutical ingredients, including Bilastine (an antihistamine molecule for allergic rhinitis, conjunctivitis, and urticaria), Calcifediol for bone metabolism, Deflazacort for treating osteoarticular diseases, Hidrosmin for venous insufficiency, and Mesalazine for digestive problems. The firm also engages in significant export activities. Founded in 1933, Faes Farma, S.A. is headquartered in Leioa, Spain.
When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.
+148.0% YoY
YoY Growth Rate
Revenue accelerating
+133.8% YoY
YoY Growth Rate
EPS growth accelerating
€5M/ year
0.8% of revenue
Below sector average (18%)
Research and development spending
Cash flow positive
€140M cash & investments
Quarterly Free Cash Flow
↑ Burn rate improving
Company generates more cash than it spends — no dilution risk from fundraising
Faes Farma, S.A. grew revenue 148% year-over-year and the growth rate is speeding up. That's the kind of momentum growth investors look for — the question is whether margins can follow.
The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.
Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.
ROIC between 15% and 25%. Every dollar invested in the business earns 15 to 25 cents back per year.
Full breakdown available with your free trial
See every metric, trend, and what it means for this stock.
Single-digit earnings growth — steady but not exciting.
Full breakdown available with your free trial
See every metric, trend, and what it means for this stock.
FCF margin between 0% and 10%. Some cash from sales, but not a lot.
Full breakdown available with your free trial
See every metric, trend, and what it means for this stock.
Interest coverage above 8. Profits cover interest many times over.
Full breakdown available with your free trial
See every metric, trend, and what it means for this stock.
P/E in the normal range. Price is roughly $15 for every $1 of yearly profit.
Full breakdown available with your free trial
See every metric, trend, and what it means for this stock.
Standard yield zone for stable dividend payers. A meaningful piece of total return.
Full breakdown available with your free trial
See every metric, trend, and what it means for this stock.
